# Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

> **NCT00407498** · PHASE1 · COMPLETED · sponsor: **Piramal Enterprises Limited** · enrollment: 50 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** P276-00

## Key facts

- **NCT ID:** NCT00407498
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2009-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407498, "Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00407498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*